Anti-TNFRSF21/DR6/CD358 Antibody is a humanized monoclonal antibody targeting Death Receptor 6 (DR6, also known as TNFRSF21). DR6 is a member of the tumor necrosis factor receptor (TNFR) superfamily containing an intracellular death domain. It plays a pivotal role in nervous system development by binding to amyloid precursor protein (APP) to trigger axon pruning and neuronal death. Additionally, DR6 is overexpressed in various tumor cells and is involved in regulating angiogenesis and cell survival. Featuring a huIgG1 heavy chain and a hu-kappa light chain, this antibody is utilized to study DR6-mediated apoptotic signaling, mechanisms of neurodegenerative diseases, and the modulation of the tumor immune microenvironment.